Article

Impact of common polymorphisms in candidate genes for insulin resistance and obesity on weight loss of morbidly obese subjects after laparoscopic adjustable gastric banding and hypocaloric diet.

Dipartimento Medicina Sperimentale e Clinica, Università Magna-Graecia di Catanzaro, Via Campanella, 115, 88100 Catanzaro, Italy.
Journal of Clinical Endocrinology &amp Metabolism (Impact Factor: 6.31). 10/2005; 90(9):5064-9. DOI: 10.1210/jc.2005-0404
Source: PubMed

ABSTRACT It is unknown whether genetic factors that play an important role in body weight homeostasis influence the response to laparoscopic adjustable gastric banding (LAGB).
We investigated the impact of common polymorphisms in four candidate genes for insulin resistance on weight loss after LAGB.
The design was a 6-month follow-up study. Setting: The study setting was hospitalized care.
A total of 167 unrelated morbidly obese subjects were recruited according to the following criteria: age, 18-66 yr inclusive; and body mass index greater than 40 kg/m2 or greater than 35.0 kg/m2 in the presence of comorbidities. Intervention: LAGB was used as an intervention.
Measure of correlation between weight loss and common polymorphisms in candidate genes for insulin resistance and obesity was the main outcome measure.
The following single nucleotide polymorphisms were detected by digestion of PCR products with appropriate restriction enzymes: Gly972Arg of the insulin receptor substrate-1 gene, Pro12Ala of the proliferator-activated receptor-gamma gene, C-174G in the promoter of IL-6 gene, and G-866A in the promoter of uncoupling protein 2 gene. Baseline characteristics including body mass index did not differ between the genotypes. At the 6-month follow-up after LAGB, carriers of G-174G IL-6 genotype had lost more weight than G-174C or C-174C genotype (P = 0.037), and carriers of A-866A uncoupling protein 2 genotype had lost more weight as compared with G-866G (P = 0.018) and G-866A (P = 0.035) genotype, respectively. Weight loss was lower in carriers of Gly972Arg insulin receptor substrate-1 genotype than Gly972Gly carriers, but not statistically significant (P = 0.06). No difference between carriers of Pro12Ala and Pro12Pro proliferator-activated receptor-gamma genotype was observed.
These data demonstrate that genetic factors, which play an important role in the regulation of body weight, may account for differences in the therapeutic response to LAGB.

0 Bookmarks
 · 
67 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the association of host genetics with changes in limb or trunk fat in a group of antiretroviral therapy (ART)-naive HIV-infected patients prospectively followed up according to the initiation and the type of ART.
    Journal of Antimicrobial Chemotherapy 07/2014; · 5.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim: Polymorphisms in uncoupling protein (UCP) genes have been strongly associated with energy expenditure and obesity. This study aimed at investigating the effects of UCP genes polymorphisms (UCP1 -3826A/G, UCP2A/V, UCP2 I/D, and UCP3 -55C/T) on change in body mass index (BMI) during a lifestyle modification program in Japanese subjects. Results: Intervention induced a significant decrease in energy intake (-8.6%±17.0%) and a significant increase in energy expenditure (7.7%±7.4%). As a result, participants experienced a significant decrease in their BMI of -1.8%±2.7%. In a multivariate regression analysis, only UCP2 D/I among the selected UCP genes polymorphisms was associated with a change in BMI independent of the effects of gender, age, baseline BMI, changes in energy intake, and expenditure. Further regression analysis revealed that, in contrast to the DD genotype group, the DI+II genotype group showed no significant association between weight loss and change in energy expenditure suggesting this polymorphism altered the effects of this parameter on change in BMI. Conclusion: The study found UCP2 D/I to be associated with change in BMI by altering the effect of change in energy expenditure on change in BMI.
    Genetic Testing and Molecular Biomarkers 10/2012; · 1.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The discovery of genetic abnormalities in obesity improves the knowledge on the physiology of energetic homeostasis, and demonstrates that it is a fully recognized disease and not only a behavioral problem. In cases of early obesity and very severe degree, with severely abnormal dietary behavior, endocrine abnormalities, and a ground of parental consanguinity, monogenic obesity or a syndromic obesity (in the case of a rare genetic disease) must be suspected. In that case, a genetic screening is necessary because it helps the global care of the patient and sometimes an effective specific therapeutics can be proposed. Except in the previous cases, oligogenic obesity (mutation of an important gene) or polygenic obesity (association of polymorphisms on various genes) are suspected. The genetic abnormalities express themselves only in association with deleterious environment. In these situations, it is not at the moment recommended to make a systematic screening in clinical practice.
    La Presse Médicale 09/2010; 39(9):921-929. · 1.17 Impact Factor

Full-text (2 Sources)

Download
33 Downloads
Available from
May 16, 2014